Hu-Lieskovan, S. et al. SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. J Immunother Cancer. 2020; 8(2): e000705.
Garg, S. K., et al. Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response. Cancers 2020, 12, 3515; doi:10.3390/cancers1213515
Wang, Z., et al. A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients. Lung Cancer 147(2020) 259-268.
Hendriks, L. E., et al. Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. Translational Lung Cancer Research 2018: 7(6):647-660
Foy JP., et al. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. Ann Oncol. 2017 Aug 1; 28(8):1934
Knudsen E., et al. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunological Markers. Clin Cancer Res. 2017 Aug 1;23(15):4429
Foy J. P. et al, The promising impact of molecular profiling on treatment strategies in oral cancers. J. Stomatol Oral Maxillofac Sur (2017) Sep; 118(4): 242-247. doi: 10.106/j.jormas.2017.05.004.Epub 2017 May 30.
Sharma P., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar 18(3):312
Page last updated November 29, 2022